NDI warning letters fuel criticism of FDA enforcement approach The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight loss results, Retatrutide BPC 157: Miracle Healing Peptide or Hidden Danger? FDA to weigh easing limits on unproven peptides The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York